Denali Therapeutics (DNLI) | Stock Overview & Key Data
Denali Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $13.62
High: $14.44
on August 8, 2025
52 Week Range
Low: $10.57
High: $33.33
on April 7, 2025
on November 11, 2024
All-Time High: $93.94 on December 21, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.1B
EPS
-2.67
P/E Ratio (TTM)
-5.44
Forward P/E
-5.22
P/B Ratio
1.86
PEG Ratio
-5.22
Div. Yield
N/A
ROE
-35.21%
Beta
1.357
Debt to Equity
4.59
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-22.58%
Return on Equity (TTM)
-35.21%
EBITDA
$-514.0M
Net Income (TTM)
$-453.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Denali Therapeutics DNLI | 2.08B Mid-cap | 3.87% | -2.58% | -3.26% | -33.14% | -33.01% | -37.56% | -63.32% | -54.37% |
| Vertex VRTX | 121.28B Large-cap | -20.68% | -21.40% | -14.68% | -22.01% | -9.67% | -21.75% | 24.45% | 37.13% |
| Regeneron REGN | 60.39B Large-cap | 0.74% | 2.78% | 2.80% | -18.45% | -21.28% | -50.23% | -10.45% | -8.09% |
| Exelixis EXEL | 10.15B Large-cap | 1.23% | -13.31% | 3.34% | 12.60% | 11.14% | 39.86% | 93.63% | 71.61% |
| BridgeBio Pharma BBIO | 8.68B Mid-cap | -1.67% | 7.85% | 33.66% | 46.66% | 65.18% | 90.71% | 301.64% | 63.30% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
9.86%
Institutional Ownership
94.20%
Shares Short
13M
Short Ratio
8.55
Short % of Shares Outstanding
9.77%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Denali Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Denali Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is DNLI's 52-week high and low?
- In the last 52 weeks, Denali Therapeutics reached a high of $33.33 (on November 11, 2024) and a low of $10.57 (on April 7, 2025).
- What is the market cap and P/E ratio for DNLI?
- Curious about Denali Therapeutics's size and valuation? Its market capitalization stands at 2.08B. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.44, and the forward P/E (looking ahead) is -5.22.
- Does DNLI pay dividends? If so, what's the yield?
- As for dividends, Denali Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Denali Therapeutics's main competitors or similar companies to consider before investing?
When looking at Denali Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX121.28B Healthcare Biotechnology -21.75% 24.45% Regeneron
REGN60.39B Healthcare Biotechnology -50.23% -10.45% Exelixis
EXEL10.15B Healthcare Biotechnology 39.86% 93.63% BridgeBio Pharma
BBIO8.68B Healthcare Biotechnology 90.71% 301.64% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Denali Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Denali Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -35.21%, the Debt to Equity ratio from the most recent quarter is 4.59, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for DNLI?
- Looking at Denali Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of DNLI stock is held by insiders and institutions?
- Wondering who owns Denali Therapeutics stock? Company insiders (like executives and directors) hold about 9.86% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 94.20%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.